762
Views
9
CrossRef citations to date
0
Altmetric
Brief Report

Association ofSOD3 promoter DNA methylation with its down-regulation in breast carcinomas

, , , , , & ORCID Icon show all
Pages 1325-1335 | Received 18 Dec 2019, Accepted 11 May 2020, Published online: 14 Jun 2020

References

  • National Cancer Institute. Bethesda M. seer cancer statistics review. 2019 April; Available from: https://seer.cancer.gov/csr/1975_2016/.
  • Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26–35.
  • Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108–3114.
  • Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752.
  • Furrukh M, Qureshi A. Treatment of breast cancer; review and updates. J Ayub Med Coll Abbottabad. 2018;30(2):264–274.
  • Faraoni I, Graziani G. Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. Cancers (Basel). 2018;10(12):487.
  • Teoh-Fitzgerald ML, Fitzgerald MP, Zhong W, et al. Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis. Oncogene. 2014;33(3):358–368.
  • Griess B, Tom E, Domann F, et al. Extracellular superoxide dismutase and its role in cancer. Free Radic Biol Med. 2017;112:464–479.
  • Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: oxidative eustress. Redox Biol. 2017;11:613–619.
  • Perry JJ, Shin DS, Getzoff ED, et al. The structural biochemistry of the superoxide dismutases. Biochim Biophys Acta. 2010;1804(2):245–262.
  • Marklund SL. Extracellular superoxide dismutase in human tissues and human cell lines. J Clin Invest. 1984;74(4):1398–1403.
  • Marklund SL, Holme E, Hellner L. Superoxide dismutase in extracellular fluids. Clin Chim Acta. 1982;126(1):41–51.
  • Hicks CL. Occurrence and consequence of superoxide dismutase in milk products: a review. J Dairy Sci. 1980;63(7):1199–1204.
  • Golden BO, Griess B, Mir S, et al. Extracellular superoxide dismutase inhibits hepatocyte growth factor-mediated breast cancer-fibroblast interactions. Oncotarget. 2017;8(64):107390–107408.
  • O’Leary BR, Fath MA, Bellizzi AM, et al. Loss of SOD3 (EcSOD) expression promotes an aggressive phenotype in human pancreatic ductal adenocarcinoma. Clin Cancer Res. 2015;21(7):1741–1751.
  • Jones PA. DNA methylation and cancer. Oncogene. 2002;21(35):5358–5360.
  • Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17:52.
  • Laukkanen MO, Mannermaa S, Hiltunen MO, et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol. 1999;19(9):2171–2178.
  • Teoh-Fitzgerald ML, Fitzgerald MP, Jensen TJ, et al. Genetic and epigenetic inactivation of extracellular superoxide dismutase promotes an invasive phenotype in human lung cancer by disrupting ECM homeostasis. Mol Cancer Res. 2012;10(1):40–51.
  • Curtis C, Shah SP, Chin S-F, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352.
  • Glück S, Ross JS, Royce M, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat. 2012;132(3):781–791.
  • Sharma P, Bhunia S, Poojary SS, et al. Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease. Tumour Biol. 2016;37(11):14687–14699.
  • Divyya S, Naushad SM, Murthy PVLN, et al. GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD. Mol Biol Rep. 2013;40(10):5541–5550.
  • Chiba T, Yokosuka O, Fukai K, et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology. 2004;66(6):481–491.
  • Lakshmi SV, Naushad SM, Reddy CA, et al. Oxidative stress in coronary artery disease: epigenetic perspective. Mol Cell Biochem. 2013;374(1–2):203–211.
  • Kamiya T, Machiura M, Makino J, et al. Epigenetic regulation of extracellular-superoxide dismutase in human monocytes. Free Radic Biol Med. 2013;61:197–205.
  • Zelko IN, Stepp MW, Vorst AL, et al. Histone acetylation regulates the cell-specific and interferon-gamma-inducible expression of extracellular superoxide dismutase in human pulmonary arteries. Am J Respir Cell Mol Biol. 2011;45(5):953–961.
  • Zelko IN, Mueller MR, Folz RJ. CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic Biol Med. 2010;48(7):895–904.
  • Chaiswing L, Zhong W, Oberley TD. Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression. Free Radic Biol Med. 2014;67:342–352.
  • Hashmi AA, Aijaz S, Khan SM, et al. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol. 2018;16(1):1.
  • Li Z-H, Hu P-H, Tu J-H, et al. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 2016;7(40):65024–65033.
  • Stefansson OA, Moran S, Gomez A, et al. A DNA methylation-based definition of biologically distinct breast cancer subtypes. Mol Oncol. 2015;9(3):555–568.
  • Griess B, Tom E, Domann F, et al. Extracellular superoxide dismutase and its role in cancer. Free Radic Biol Med. 2017;112:464–479.
  • Singh RK, Indra D, Mitra S, et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet. 2007;122(1):71–81.
  • Beder LB, Gunduz M, Ouchida M, et al. Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest. 2003;83(1):99–105.
  • Dallol A, Da Silva NF, Viacava P, et al. SLIT2, a human homologue of the drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res. 2002;62(20):5874–5880.
  • Kim G-J, Cho S-J, Won N-H, et al. Genomic imbalances in Korean hepatocellular carcinoma. Cancer Genet Cytogenet. 2003;142(2):129–133.
  • Pershouse MA, El-Naggar AK, Hurr K, et al. Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene. 1997;14(3):369–373.
  • Polascik TJ, Cairns P, Chang WY, et al. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res. 1995;55(22):5396–5399.
  • Sherwood JB, Shivapurkar N, Lin WM, et al. Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants. Gynecol Oncol. 2000;79(1):90–96.
  • Shivapurkar N, Maitra A, Milchgrub S, et al. Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum Pathol. 2001;32(2):169–177.
  • Shivapurkar N, Sood S, Wistuba II, et al. Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res. 1999;59(15):3576–3580.
  • Shivapurkar N, Virmani AK, Wistuba II, et al. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res. 1999;5(1):17–23.
  • Kwei KA, Kung Y, Salari K, et al. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol. 2010;4(3):255–266.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.